Skip to main content
. 2020 Aug 19;55(5):262–271. doi: 10.1136/bjsports-2019-101268

Table 1.

Baseline characteristics of participants (n=256) by treatment groups

Key characteristics Overall US-guided injection plus physiotherapist-led exercise US-guided injection plus leaflet Unguided injection plus physiotherapist-led exercise Unguided injection plus leaflet
n=256 n=64 n=64 n=64 n=64
Non-clinical characteristics
Age, mean (SD) 53.8 (10.2) 55.6 (10.5) 54.8 (10.0) 51.9 (10.7) 53.0 (9.5)
Females, n (%) 133 (52.0) 37 (57.8) 29 (45.3) 45 (70.3) 22 (34.4)
Previous or current smokers, n (%) 139 (54.3) 29 (45.3) 38 (59.4) 36 (56.3) 36 (56.3)
Right handed, n (%) 217 (84.8) 59 (92.2) 52 (81.3) 51 (79.7) 55 (85.9)
Currently in paid job, n (%) 141 (55.1) 31 (48.4) 35 (54.5) 34 (53.1) 41 (64.1)
Time off work in past 12 months because of shoulder problem, n (%) 44 (29.3) 10 (28.6) 13 (36.1) 8 (22.9) 13 (29.6)
Shoulder pain interference with work (NRS scale; 0–10) mean (SD) 4.8 (2.9) 4.6 (3.0) 5.2 (2.8) 4.2 (3.0) 4.9 (2.9)
Live alone, n (%) 39 (15.4) 10 (15.9) 12 (18.8) 7 (11.1) 10 (15.9)
Clinical characteristics
SPADI,* mean (SD)
 Pain subscale score 70.6 (15.5) 69.1 (17.3) 72.9 (14.8) 70.9 (15.6) 69.4 (15.5)
 Disability subscale score 55.1 (21.5) 54.3 (22.4) 57.3 (21.1) 57.1 (19.3) 51.6 (22.9)
 Total SPADI score 61.1 (18.1) 60.0 (19.2) 63.4 (17.6) 62.4 (16.5) 58.4 (18.9)
Pain severity today (NRS scale; 0–10), mean (SD) 5.7 (2.0) 5.6 (2.1) 5.9 (2.0) 5.4 (1.9) 5.8 (2.0)
Both shoulders affected, n (%) 20 (7.8) 7 (10.9) 3 (4.7) 5 (7.8) 5 (7.8)
Duration of shoulder pain, n (%)
 <3 months 28 (10.9) 6 (9.4) 5 (7.8) 8 (12.5) 9 (14.0)
 3–6 months 50 (19.5) 16 (25.0) 13 (20.3) 9 (14.0) 12 (18.8)
 6–12 months 74 (28.9) 17 (26.6) 18 (28.1) 26 (40.6) 13 (20.3)
 >12 months 104 (40.6) 25 (39.1) 28 (43.8) 21 (32.8) 30 (46.9)
Previous episode of shoulder pain, n (%) 87 (34.0) 16 (25.0) 24 (37.5) 17 (26.6) 30 (46.9)
Troubled by shoulder pain in bed most or every night, n (%) 205 (80.1) 48 (75.0) 51 (79.7) 51 (79.7) 55 (85.9)
Pain self-efficacy scale,† mean (SD) 35.6 (15.3) 35.2 (15.3) 35.4 (13.7) 34.9 (14.0) 36.7 (10.8)
Fear of movement,‡ mean (SD) 27.0 (5.1) 28.0 (5.4) 27.2 (4.8) 26.4 (4.6) 26.4 (5.4)
SF-12-PCS§, mean (SD) 38.1 (9.7) 37.3 (8.9) 38.5 (9.5) 38.1 (10.9) 38.5 (9.8)
SF-12-MCS¶, mean (SD) 47.2 (12.6) 47.9 (12.7) 46.8 (13.3) 45.8 (12.4) 48.1 (12.2)
Other health conditions,** n (%) 137 (53.5) 38 (59.4) 32 (50.0) 37 (57.8) 30 (46.9)
Widespread pain, n (%) 62 (24.8) 15 (23.8) 19 (30.7) 17 (26.6) 11 (18.0)
BMI categories, n (%)
 Normal/underweight 74 (29.5) 17 (26.6) 17 (26.6) 22 (36.1) 18 (29.0)
 Overweight 62 (24.7) 22 (34.4) 13 (20.3) 12 (19.7) 15 (24.2)
 Obese/morbidly obese 115 (45.8) 25 (39.1) 34 (53.1) 27 (44.3) 29 (46.8)

*Shoulder Pain and Disability Index=Primary outcome measure (each scale/subscale ranges from 0 to 100; 0=no pain/difficulty, 100=worst pain/so difficult it required help).

†10 item scale, score range=0–60 (0=not at all confident, 60=completely confident).

‡Assessed using Tampa scale for kinesiophobia-11– score range from 11 to 44 with higher scores reflecting greater fear of movement or (re)injury.

§SF PCS.

¶SF MCS (scales based on ‘Normalised’ general population average of 50 with SD 10).

**Health conditions include chest problems, heart problems, deafness, problems with eyesight (excluding need for glasses), raised blood pressure, diabetes, stroke, cancer, liver disease, kidney disease and circulation problems in the legs.

BMI, body mass index; MCS, Mental Component Scale; NRS, Numeric Rating Scale; PCS, Physical Component Scale; SF-12, Short Form-12; SPADI, Shoulder Pain and Disability Index; US, ultrasound.